title: Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
authors.forename: Francesco
authors.initials: F
authors.lastname: Ciccia
authors.forename: Annarita
authors.initials: A
authors.lastname: Giardina
authors.forename: Aroldo
authors.initials: A
authors.lastname: Rizzo
authors.forename: Giuliana
authors.initials: G
authors.lastname: Guggino
authors.forename: Paola
authors.initials: P
authors.lastname: Cipriani
authors.forename: Francesco
authors.initials: F
authors.lastname: Carubbi
authors.forename: Roberto
authors.initials: R
authors.lastname: Giacomelli
authors.forename: Giovanni
authors.initials: G
authors.lastname: Triolo
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007378:Interleukins / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D012469:Salivary Glands / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D016896:Treatment Outcome; D000097043:Interleukin-22
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D007378:Interleukins; D000069283:Rituximab; D000097043:Interleukin-22